media centre
oNKo-innate named Australian Emerging Company of the Year 2021
27 October

media centre
All media
All media
Twitter
Feed
news
news
publications
publications
RT @jcarrollmonash: Many congratulations...
RT @Dr_Nick_Bikes: Fantastic recognition...
@cushionpuff @AusBiotech @JNJInnovation ...
RT @AusBiotech: Congrats to @oNKo_innate...
We are humbled and grateful to be recogn...
RT @richberry1983: Fantastic recognition...
RT @chaks86: Great recognition for a you...
oNKo-innate named Australian Emerging Company of the Year 2021
RT @cmdenardo: And just like that, I’m...
We are honoured to be recognised as Aust...
RT @Dr_Nick_Bikes: Fascinating discovery...
RT @Dr_Nick_Bikes: @Daily_Experts Blood ...
RT @MonashUni: We’re delighted to rece...
RT @alastair_hick: We are hiring! Univer...
RT @Dr_Nick_Bikes: More recently, clinic...
RT @Dr_Nick_Bikes: I fondly remember pre...
RT @Dr_Nick_Bikes: Having proven the CIS...
RT @Dr_Nick_Bikes: We coined the term "i...
RT @Dr_Nick_Bikes: In every subsequent N...
RT @Dr_Nick_Bikes: Indeed, Cish is a STA...
RT @Dr_Nick_Bikes: 2 years later Yoshimu...
RT @Dr_Nick_Bikes: Cish should have been...
RT @Dr_Nick_Bikes: We investigated wheth...
RT @Dr_Nick_Bikes: 2011-2014 I was inves...
RT @Dr_Nick_Bikes: #CISH trending on Twi...
RT @Dr_Nick_Bikes: Very pleased to see o...
RT @Dr_Nick_Bikes: Proud of the team. Ou...
RT @Dr_Nick_Bikes: Registrations are lim...
Come join our team! We have an exciting ...
Ready for a new role at the cutting edge...
The cancer–natural killer cell immunity cycle
Monash University and oNKo-innate Announce Research Partnership
Onko-Innate, Gilead, Kite Work On NK Cancer Immunotherapies
Immunotherapy biotech scores Gilead partnership
Interest builds in next-generation cancer immunotherapies
Gilead, oNKo-innate to develop NK cells-focused cancer immunotherapies
Gilead, Kite pen natural killer pact with little-known Australian cell therapy player
Amid remdesivir craze Gilead finds time for another oncology pact — looping in all things NK cells
Announcing research collaboration with Gilead and Kite
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response
A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients
Quantifying NK cell growth and survival changes in response to cytokines and regulatory checkpoint blockade helps identify optimal culture and expansion conditions
Congratulations to our CSO for winning the 2019 Jacques Miller Medal
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Molecular insight into targeting the NK cell immune response to cancer
The life and death of immune cell types: the role of BCL-2 anti-apoptotic molecules
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
IL-15 signaling in NK cell cancer immunotherapy
Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis
Targeting natural killer cells in cancer immunotherapy
CIS is a potent checkpoint in NK cell-mediated tumor immunity
A crucial role for the homeodomain transcription factor Hhex in lymphopoiesis
IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo